Skip to content

Brian Rittenhouse

Professor of Social and Administrative Sciences

Department: School of Pharmacy
Office: MATR 4006H

Contact: brian.rittenhouse@mcphs.edu
(P) 617.732.2168



Schools

School of Pharmacy

Programs

Pharmaceutical Economics and Policy (MS)
Pharmaceutical Economics and Policy (PhD)

Education

University of Wisconsin-Madison: Ph.D. Economics, 1988
University of Wisconsin-Madison: M.S. Economics, 1983
Oberlin College, B.A. Economics, 1979


Research Interests

Health Economics
Economic Evaluation


Peer-Reviewed Articles & Book Chapters

Peer-Reviewed Journals

M Alsheikh, E Seoane-Vazquez, B Rittenhouse, ER. Fox, J Fanikos. A Comparison of Drug Shortages in the Hospital Setting in the United States and Saudi Arabia: An Exploratory Analysis. Hospital Pharmacy. 2016, May 51(5), 370-375

Rittenhouse BE “Pricing Calculations” Neurology 2015 [electronic response to Hartung et al, “The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail Online letter, June 18, 2015 ; see also: authors’ response and Editor’s thanks, June 30, 2015,

D Nathwani, J. Li, D. Balan, R J. Willke, B. Rittenhouse, E Mozaffari, T Tang, M Tavakoli “Economic evaluation of linezolid versus teicoplanin for the treatment gram-positive bacterial infections in hospitalized patients in Europe: results from a multi-centre trial” International Journal of Antimicrobial Agents 2004 Apr, 23(4):315-24

H López, J Li,D. Balan, RJ. Willke, B Rittenhouse, E Mozaffari, T Tang “Economic evaluation of linezolid versus teicoplanin for the treatment gram-positive bacterial infections in hospitalized patients in South/Latin America: results from a multi-centre trial” Clinical Therapeutics 2003 Jun 25(6):1846-71.

JZ Li, RJ Willke, B. Rittenhouse, MJ Rybak “Effect of linezolid versus vancomycin on hospital length of stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant Staphylococcus species: results from a randomized clinical trial”, Surgical Infections 2003 4(1): 45-58.

A Vinken ,Li J, Balan, D, Rittenhouse BE, Willke RJ, “Economic evaluation of linezolid, oxacillin and vancomycin in the empirical treatment of cellulitis in US hospitals: a decision analytical model” American Journal of Therapeutics 2003 Jul-Aug; 10(4):264-74

RJ Willke, Glick HA, Li J, Rittenhouse BE, “Effects of Linezolid on Hospital Length of Stay Compared to Vancomycin in Treatment of Methicillin-Resistant Staphylococcus Infections: An Application of Multivariate Survival Analysis”, Intl J Tech Assessment in Health Care 18:3 (2002), 540-554.

Li, J, Willke, RJ, Rittenhouse, BE, Glick H “Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococci species infections” Pharmacotherapy 2002; 22(2): 45S-54S.

A Vinken ,Li J, Balan, D, Rittenhouse BE, Willke RJ, Nathwani D, “Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model” J of Hospital Infections 2001; 49 (Supplement A): S13-S24

Zhiming Li, Z., Willke, RJ, Pinto, LA, Rittenhouse, BE, et al “Reduction in Hospital Length of Stay (LOS) in Patients with Known or Suspected Methicillin-Resistant Staphylococcus species Infections Treated with Linezolid Compared to Vancomycin: A Randomized, Multi-Center Trial” Pharmacotherapy 2001; 21(3): 263-274

Rittenhouse, B, Stinnett, A., Dulisse, B, et al. “An Economic Evaluation of Levofloxacin in the Outpatient Treatment of Adults with Community-Acquired Pneumonia” American Journal of Managed Care. 2000; 6(3):91-99.

Rittenhouse, B, Dulisse, B, Stinnett, A. “What Price Significance? The Effect of Price Estimates on Statistical Inference in Economic Evaluation” Health Economics. 1999; 8:213-19.

Rittenhouse, B, Stinnett, A., Dulisse, B, et al. “An Economic Evaluation of Levofloxacin in the Inpatient Treatment of Adults with Community-Acquired Pneumonia” Pharmacy & Therapeutics. 1999; 24(4):169-79.

Rittenhouse, B., Choiniere, M. “An economic evaluation of pain therapy after hysterectomy: Choiniere, M. Rittenhouse, B. et al. “Efficacy and costs of pain therapy in hysterectomized patients: Comparison between patient-controlled analgesia and regular intramuscular opioid therapy.” Anesthesiology. 1998; 89:1377-88.

Rittenhouse B. "Exorcising Protocol-induced Spirits: Making the Clinical Trial Relevant for Economics." Medical Decision Making, 1997, 17(3):331-39.

Rittenhouse B. “Healthy Years Equivalents v. Time Trade Off: Resolving Ambiguity on Certainty and Uncertainty.”, International Journal of Technology Assessment in Health Care, 1997, 13(1): 35-48.

Rittenhouse B. “Is there a Need for Methods Standardization in Economic Evaluation?”, Medical Care. Supplement: Proceedings of “Standards for Economic Evaluation of Drugs: Issues and Answers.”1996;34(12):DS13-DS22.

Rittenhouse B. “The Standards Debate: What Have We Learned?”, Medical Care. Supplement: Proceedings of “Standards for Economic Evaluation of Drugs: Issues and Answers.” 1996;34(12):DS5-DS10.

Rittenhouse B. "A Novel Compliance Assessment Technique: The Randomized Response Interview.", International Journal of Technology Assessment in Health Care, 1996; 12(3):498-510.

Rittenhouse, B. "Respondent-Specific Information from the Randomized Response Interview." J Clin Epidemiol (1996); 49(5):545-49.

Rittenhouse B. "Another Deficit Problem: The Deficit of Relevant Information when Clinical Trials are the Basis for Pharmacoeconomic Research." Journal of Research in Pharmaceutical Economics (1996: 7(3) pp. 3-15).

Rittenhouse B. "The Relevance of Searching for Effects Under a Clinical Trial Lamp Post: A Key Issue." Medical Decision Making 1995; 15(4): 348-357.

Rittenhouse B. "Potential Inconsistencies between Cost-Effectiveness and Cost-Utility Analyses: An Upstairs/Downstairs Socioeconomic Distinction." International Journal of Technology Assessment in Health Care 1995; 11(2):365-376.

Rittenhouse B. "Teaching the Tools of Pharmaceutical Care Decision-Analysis." American Journal of Pharmaceutical Education 58 (Winter 1994): 431-36.

Rittenhouse B. "Economic Incentives and Disincentives for Efficient Prescribing." Pharmacoeconomics 1994; 6(3):222-232.

Grabenstein J, Hartzema A, Guess H, Johnston W, Rittenhouse B. "Community Pharmacists as Immunization Advocates: Cost Effectiveness of a Cue to Influenza Vaccination." Medical Care 1992; 30(6).

Books/Book Chapters/Monographs

Morris-Blank C. and Rittenhouse B. (Eds.) Medical Care Supplement: Proceedings of “Standards for Economic Evaluation of Drugs: Issues and Answers,” 1996.

Rittenhouse B. The Uses of Models in the Economic Evaluation of Medicines, Office of Health Economics, London, October, 1996.

Rittenhouse B. "Designing and Conducting Cost-Effectiveness and Cost-Minimization Analyses." In: B. Spilker, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven Pub. 1996.

Rittenhouse B, O'Brien B. "Threats to the Validity of Pharmacoeconomic Analyses Based on Clinical Trial Data." In: B. Spilker, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven Pub. 1996.

Rittenhouse B. Issues in the Economic Evaluation of Pharmaceuticals. Japanese Journal of Health Economics and Policy (Supplement) Institute for Health Economics and Policy, Tokyo, Japan, 1995.

Rittenhouse B. Interview with Dr. Philip G. Boysen on Economic Evaluation Issues for Point Counterpoint: Controversial Issues Confronting the Intensive Care Specialist, 4(4), 1996.

Rittenhouse B. “Gesundheitsökonomie - Bewertung des Screenings und seiner Nutzeffekte.” (Health Economics: The Economics of Screening and Outcome Valuation) In: P. Faul and J. E. Altwein (eds.), Screening des Prostatakarzinoms. Springer-Verlag, Berlin, 1995.

Rittenhouse B. Interview with Shunya Ikeda (discussion of economic evaluation issues for Japanese Medical Association), JAMIC Journal, August 1995:34-39.

Rittenhouse B. Review of L. Russell’s Educated Guesses: Making Policy about Medical Screening Tests. University of California Press, Berkeley, 1994. In: Iryo Keizai Kenkyu Kikou Letter (Institute for Health Economics and Policy Newsletter), Tokyo, Japan; No. 20, June 1995.

Rittenhouse B, Erickson P. Pharmacoeconomic and Quality of Life Evaluations, Schering-Plough, Kenilworth, NJ, 1992.

Brandt A, Rittenhouse B, eds. Guide to the Socioeconomic Analysis of Medical Therapies, CIBA-GEIGY, Pharma Economics, Basel, January 1990.

Rittenhouse B. Introduction to Economic Evaluation: Contributions to Health-Care Policy and Economics. CIBA-GEIGY, Pharma Policy and Economics, March 1989.

Recent Research

S. Alolayan, T. Eguale, A. Segal, J. Doucette, B. Rittenhouse , Heterogeneity of treatment effect in the diabetes prevention program: high baseline risk of developing diabetes may provide a place for metformin in prediabetes treatment that using overall sample average costs and effects masks; Accepted, but not presented at Annual European ISPOR Conference, Barcelona, November 2018

M. Algarni, B. Rittenhouse, American college of medical genetics (ACMG) newborn screening (NBS) recommendations: sensitivity to accounting for reported missing data in the case of glutaric aciduria II (GAII), Accepted, but not presented at Annual European ISPOR Conference, Barcelona, November 2018

S. Alolayan, T. Eguale, A. Segal, J. Doucette, B. Rittenhouse, Re-analysis of the diabetes prevention program 3 year cost-effectiveness analysis (CEA) using identical data but proper methods questions its conclusions, Accepted, but not presented at Annual European ISPOR Conference, Barcelona, November 2018

S. Alolayan, T. Eguale, A. Segal, J. Doucette, B. Rittenhouse , Re-analysis of the diabetes prevention program (DPP) 3 year cost-effectiveness analysis (CEA) using identical data but proper QALY calculations may revive its metformin conclusions, Accepted, but not presented at Annual European ISPOR Conference, Barcelona, November 2018

S. Alolayan, T. Eguale, A. Segal, J. Doucette, B. Rittenhouse, Reevaluating a 10 year cost-effectiveness analysis (CEA) of the diabetes prevention program outcomes study (DPP/DPPOS): clarifying the previous confusion, Accepted, but not presented at Annual European ISPOR Conference, Barcelona, November 2018

S. Alolayan, T. Eguale, A. Segal, J. Doucette, B. Rittenhouse , Can missing data boundary estimates cast doubt on previous conclusions reevaluating a 10 year cost-effectiveness analysis (CEA) of the diabetes prevention program study (DPP/DPPOS)?, Accepted, but not presented at Annual European ISPOR Conference, Barcelona, November 2018

D. Hariharan, K. Daniels, R. Kodeih, J. Amamoo, I. Sultan, B. Rittenhouse, A cost effectiveness analysis (CEA) of phenytoin (PHT) versus levetiracetam (LEV) for early seizure pharmacoprophylaxis after traumatic brain injury (TBI) from a US institutional perspective: an upgrade of a cost minimization analysis (CMA); ISPOR North American Annual Meeting, May 2018, Baltimore, MA

A. Alfraih, B, Rittenhouse, Calculating appropriate ICERs in diabetes prevention program (DPP) cost-effectiveness and overturning misleading conclusions regarding optimal treatment; ISPOR North American Annual Meeting, May 2018, Baltimore, MA

A. Redlich, B. Rittenhouse, Examining the effect of missing data on the ACMG newborn screening criteria of least consensus for carnitine palmitoyltransferase II deficiency (CPT II); ISPOR North American Annual Meeting, May 2018, Baltimore, MA

M. Algarni, B. Rittenhouse, A systematic review of cost-effectiveness analysis studies in newborn screening (NBS); ISPOR North American Annual Meeting, May 2018, Baltimore, MA

B. Rittenhouse, Accounting for known unknowns in the American College of Medical Genetics (ACMG) recommendations for NBS: policy implications of accounting for uncertainty in assessment in the case of medium chain ketoacyl-coa thiolase deficiency (MCKAT) newborn screening (NBS); ISPOR North American Annual Meeting, May 2018, Baltimore, MA

R. Kodeih, B. Rittenhouse, American College of Medical Genetics (ACMG) recommendations for newborn screening (NBS) for biotinidase deficiency (BIOT): the influence of uncertainty due to missing data; ISPOR North American Annual Meeting, May 2018, Baltimore, MA

K. Daniels, B. Rittenhouse, The analysis of missing data around the American College of Medical Genetics (ACMG) recommendations for newborn screening (NBS) of maple syrup urine disease (MSUD) ; ISPOR North American Annual Meeting, May 2018, Baltimore, MA

PSY72. Alsumali A, Al-Hawage A, Rittenhouse B, Seoane E, Eguale T. Systematic Assessment of Decision Analytic Models for the Cost Effectiveness of Bariatric Surgery. ISPOR North American Annual Meeting, May 2017, Boston, MA

PSY74. Alsumali A, Eguale T, Bairdain S, Rittenhouse B, Seoane E, Samnaliev M. Cost Effectiveness of Bariatric Surgery for Morbid Obesity in USA. ISPOR North American Annual Meeting, May 2017, Boston, MA

PSY145. Alsheikh M, Rittenhouse B. Examining Uncertainty around the American College of Medical Genetics (ACMG) Recommendations for Newborn Screening (NBS) for Defects of Biopterin Cofactor Biosynthesis (BIOPT BS) Using Manski Bounds and Bootstrapping. ISPOR North American Annual Meeting, May 2017, Boston, MA

PMD8. Ndikumukiza C, Rittenhouse B. Examining Uncertainty around the American College of Medical Genetics (ACMG) Recommendations for Newborn Screening (NBS) for Hypermethioninemia (MET). ISPOR North American Annual Meeting, May 2017, Boston, MA

PMD117. Moon J, Rittenhouse B. Examining Uncertainty around the American College of Medical Genetics (ACMG) Recommendations for Newborn Screening (NBS) for Medium/Short Chain L-3-OH ACYL-COA DH Deficiency (M/SCHAD). ISPOR North American Annual Meeting, May 2017, Boston, MA

PMD124. Hariharan D, Rittenhouse B. Examining Uncertainty around the American College of Medical Genetics (ACMG) Recommendations for Newborn Screening (NBS) for Cystic Fibrosis (CF). ISPOR North American Annual Meeting, May 2017, Boston, MA

PDB46. Alolayan SO, Rittenhouse B. Clarifying Conclusions from a Cost-Effectiveness Analysis of the Diabetes Prevention Program (DPP) and its Outcomes Study (DPPOS). ISPOR North American Annual Meeting, May 2017, Boston, MA

Alharbi A, Rittenhouse B (2016) Examining uncertainty around American College of Medical Genetics (ACMG) recommendations for newborn screening for citrullenimia type 2 (CIT II) 2016 SMDM Annual North American meeting Vancouver, BC, Canada; https://smdm.confex.com/smdm/2016bc/webprogram/Paper10184.html

Bojan B, Rittenhouse B, (2016) Examining uncertainty around American College of Medical Genetics (ACMG) recommendations for newborn screening for galactose epimerase deficiency (GALE), Value in Health 19(3) A38, ISPOR 2016 North America conference

Yang K, Rittenhouse B, (2016) Impact of missing data in criteria of least consensus on ACMG newborn screening recommendations for short-chain acyl-coa dehydrogenase deficiency, Value in Health 19(3) A38, ISPOR 2016 North America conference

Algatan, R Rittenhouse B, (2016) Examining uncertainty around the American College of Medical Genetics (ACMG) recommendation for newborn screening for 2-methylbutyryll-coa dehydrogenase deficiency (2MBG), Value in Health 19(3) A39, ISPOR 2016 North America conference

Alharbi, A, Rittenhouse B, (2016) Examining uncertainty around American College of Medical Genetics recommendations for newborn screening for citrullenimia type 2 using Manski bounds, Value in Health 19(3) A307, ISPOR 2016 North America conference

Alotaibi A, Alsheikh M, Mahida SR, Rittenhouse B (2015), Exploring cost-effectiveness heterogeneity by state: Using state-level vs. national disease incidence in newborn screening (NBS) cost-effectiveness analysis of congenital adrenal hyperplasia (CAH), Value in Health 18(7) A755, 18th Annual European ISPOR Conference, 2015, Milan, Italy

Alzarea A, Alolayan S, Almutairi H, Alqahtani SS, Rittenhouse B (2015), Re-evaluating the cost-effectiveness of screening for congenital adrenal hyperplasia (CAH): The sensitivity to choice of distributions in probabilistic sensitivity analyses (PSAs) Value in Health 18(7) A668, 18th Annual European ISPOR Conference, 2015, Milan, Italy

Alnafesah A, Rittenhouse B (2015), Variation in state-level vs. national incidence in rare genetic disease: A Monte Carlo simulation to examine sampling variation as a primary explanation in congenital adrenal hyperplasia Value in Health 18(7) A751, 18th Annual European ISPOR Conference, 2015, Milan, Italy

Almutairi, R, Rittenhouse B (2015) “ Getting the full picture: the importance of extrapolating beyond the data” Value in Health 18(3) A10-A11, ISPOR 2015 North America poster

Algarni, M Almutairi H, Rittenhouse B (2015) “Why ask if you know? ACMG’s potential errors in making newborn screening (NBS) recommendations from using surveyed opinions for incidence scoring when actual data are available” Value in Health 18(3) A305-A306, ISPOR 2015 North America poster

Rittenhouse B “The effect of a likely overemphasis on efficiency-related test attributes on ACMG recommendations for newborn screening (NBS)” ISPOR Europe 2014 poster

Mahida S, Algarni M and Rittenhouse B “Effect of excluding non-patient benefits as an element on ACMG newborn screening (NBS) recommendations” ISPOR Europe 2014 poster

Rittenhouse B “The importance of fact over opinion in choice of conditions to be recommended for newborn screening (NBS)” ISPOR North America 2014 poster

Alotaibi A, Alansari K and Rittenhouse B “Changes and variation in conditions for newborn screening: state-specific conditions screened vs. ACMG recommendations contrasted with Europe” ISPOR North America 2014 poster

Alotaibi A and Rittenhouse B “Estimated Error in Using National Incidence Figures vs. State Estimates for Rare Disease Calculations of Estimated Cases and Cost per Case Detected in Newborn Screening (NBS): Congenital Adrenal Hyperplasia (CAH) and Congenital Hypothyroidism (CH)” ISPOR North America 2014 poster